ESPE Abstracts

Key words: neonates, hypoglycemia, size for gestational age, gender, mode of delivery.Introduction: Neonatal hypoglycemia is one of the most common treatable metabolic disorders. Universal newborn screening for hypoglycemia is primordial in detecting persistent hypoglycemia and asymptomatic episodes in order to save neonates from adverse neurological outcomes and brain injury.Objectives:</s...

Keywords: Pre-pregnancy BMI, gestational weight gain, pregnancy outcomes, neonatal outcomes.Background: Overweight and obesity epidemic is still expanding, and it is affecting women of childbearing age. Multiple studies have shown unmatched results concerning the effect of Body Mass Index (BMI) besides gestational weight gain (GWG) on pregnancy and neonatal outcomes.Objectives: Thi...

Key words: girls, small for gestational age, thelarche, pubarche, menarche.Background: Small for gestational age (SGA) babies are more prone to have an earlier onset of pubertal development and menarche. We conducted a study comparing the first menarche of small for gestational age (SGA) to appropriate for gestational age (AGA) girl newborns.Objective: The objective of the study is...

Keywords: Retrospective descriptive study, diabetes mellitus type 1, diabetic ketoacidosis, NDS-UMC, Byblos, Lebanon, single-center experience.Background: Type 1 diabetes mellitus (T1DM) increases worldwide especially in the Mediterranean region. Epidemiological studies about T1DM are made in many countries, but Lebanon lacks such data.Objective: This is a descriptive study of demo...

Background: Acrodysostosis Type 2 (ACRDYS2) is a rare autosomal dominant skeletal dysplasia associated with intellectual disability and gain-of-function mutations in the phosphodiesterase type 4D gene (PDE4D) which, in turn, leads to a paucity of intracellular cAMP due to increased PDE4D activity. This increased PDE4 activity may be due to a greater existence of a mutant monomeric form of PDE4D. To date, the clinical use of PDE4 inhibitors in ACRDYS2 has been ...

Objectives: Achondroplasia (ACH), caused by a mutation in the fibroblast growth factor receptor 3 gene (FGFR3), leads to inhibition of endochondral bone growth. Vosoritide is a biological analogue of C-type natriuretic peptide (CNP), a potent stimulator of endochondral bone growth. A Phase 2, open-label, sequential cohort, dose-escalation study was conducted to evaluate the safety, tolerability, and efficacy of vosoritide for 24 months in children with ACH aged 5&#150...

Background: Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) is worldwide the most common autosomal recessive disorder caused by defects in the CYP21A2 gene.Objective: The main objective of the study was to evaluate CAH in Cyprus over a 10 year period.Methods: All known patients were included in a population retrospective subset analysis of Cypriot patients with confirmed CAH and their clinica...

Background: Childhood obesity is a major global and European public health problem. The need for community-targeted actions has long been recognized, however it has been prevented by the lack of monitoring and evaluation framework, and the methodological inability to objectively quantify the local community characteristics in a reasonable timeframe. Recent technological achievements in mobile and wearable electronics and Big Data infrastructures allow the engagement of Europea...

Background: Obesity in childhood and adolescence represents a major health problem of our century, and accounts for a significant increase in morbidity and mortality in adulthood.Objective and hypotheses: To investigate the effectiveness of a comprehensive and personalized plan of action in the prevention and management of overweight and obesity in childhood and adolescence.Method: 470 children and adolescents (mean age±SEM: 9...

Introduction: Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is a rare, autosomal disorder characterized by deficiency of cortisol and oftentimes aldosterone, elevated adrenocorticotropic hormone (ACTH), and excess androgen production. In a phase 2 study of adolescents with classic 21OHD, 14 days of treatment with the corticotropin-releasing factor type 1 receptor (CRF1) antagonist, crinecerfont, led to median percent red...